Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To assess the impact of MK-3102 25 mg q.w. on time to confirmed CV outcomes as measured by the time to first event in the CV composite endpoint of CV-related death, nonfatal MI, nonfatal stroke, or unstable angina requiring hospitalization. To assess the effect of treatment with MK-3102 25 mg q.w. compared with placebo on A1C at 4 months. To demonstrate the non-inferiority of MK-3102 (omarigliptin) compared with placebo (against a background of standard of care) on the time to first occurrence in the composite endpoint of cardiovascular death, nonfatal MI or non-fatal stroke.
Inclusion criteria
- Type 2 diabetes mellitus